Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Archive

EnergyPathways, Vaultz Capital, Bango, hVIVO, Shield Therapeutics, Genflow Biosciences - Small Cap Week in Review

EnergyPathways, Vaultz Capital, Bango, hVIVO, Shield Therapeutics, Genflow Biosciences - Small Cap Week in Review

EnergyPathways PLC (AIM:EPP) has brought Siemens Energy on board to help design its MESH energy storage project. The system aims to store hydrogen, gas and compressed air offshore to ease grid pressure and back up renewables. Watch more

Vaultz Capital PLC (AQSE:V3TC) added another 20 Bitcoin to its treasury, now holding 70 in total. It also secured 20 petahashes of cloud mining power to support the Bitcoin network’s decentralisation. Watch more

Bango PLC (AIM:BGO, OTCQX:BGOPF) grew first half annual recurring revenue by 21% to £15.6 million and signed seven new DVM customers worldwide. The company also appointed Canaccord as its new broker, aiming to deepen US investor engagement and refresh its shareholder base.hVIVO PLC (AIM:HVO) brought in £24 million in first-half revenue, boosted by new acquisitions and strong lab services. It’s now aiming for £47 million for the year, with a solid order book and pipeline. Watch more

Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) nearly doubled Q2 revenue to $12.8 million, hitting a record 47,000 prescriptions for ACCRUFeR. It’s aiming for cash flow break-even in 2025, helped by new markets and a Viatris partnership. Watch more

Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) is preparing for human trials in Europe for its lead gene therapy, GF-1002. It’s also progressing a trial in ageing dogs as it explores a partnership in the animal health space. Watch more

Follow us and subscribe on YouTube, our social channels and on proactiveinvestors.co.uk.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK